{"id":"W4390590466","doi":"10.1093/oncolo/oyad337","title":"CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Astellas Pharma; Ipsen; Clovis Oncology; Gilead Sciences; Eisai; Daiichi Sankyo Europe; Sanofi; Instituto de Salud Carlos III; Amgen; Pfizer; PharmaMar; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Oncolytics Biotech","keywords":"Medicine; Hazard ratio; Internal medicine; Chemotherapy; Breast cancer; Oncology; Confidence interval; Progression-free survival; Randomized controlled trial; Gastroenterology; Cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005021257,0.001361613,0.002371191,0.0003381325,0.0002507592,0.001028841,0.0006742516,0.001007873,0.002672264],"category_scores_gemma":[0.004178536,0.0003942371,0.002178107,0.0004392913,0.0008761958,0.0007968256,0.0004439777,0.001850949,0.0003784773],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008169124,"about_ca_system_score_gemma":0.001005986,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006385539,"about_ca_topic_score_gemma":0.001750378,"domain_scores_codex":[0.997655,0.001873002,0.00008268586,0.0001664098,0.00009589504,0.0001270044],"domain_scores_gemma":[0.9971161,0.001340879,0.000797293,0.0002404256,0.0001033496,0.0004019669],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9844778,0.001518489,0.001856017,0.0003855494,0.001320726,0.000016806,0.00002804889,0.0003442787,0.0009555329,0.00008441845,0.0003358788,0.0086765],"study_design_scores_gemma":[0.9092157,0.07553292,0.008566652,0.00009995802,0.003639463,0.00005983521,0.00003599913,0.0007333318,0.000587263,0.0003222509,0.001184739,0.0000219528],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9809914,0.01275419,0.00058938,0.0008894095,0.0002974694,0.001358781,0.001296769,0.00004093192,0.00178156],"genre_scores_gemma":[0.987895,0.004298772,0.001158254,0.0007984799,0.0004485111,0.001802146,0.001727849,0.00002473871,0.001846389],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005021257,"threshold_uncertainty_score":0.0265553,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05329712438884447,"score_gpt":0.4183184199007502,"score_spread":0.3650212955119057,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}